WO2015151005A3 - Analogue compounds of the caffeic acid phenethyl ester and the use thereof for preventing and treating cancer - Google Patents

Analogue compounds of the caffeic acid phenethyl ester and the use thereof for preventing and treating cancer Download PDF

Info

Publication number
WO2015151005A3
WO2015151005A3 PCT/IB2015/052297 IB2015052297W WO2015151005A3 WO 2015151005 A3 WO2015151005 A3 WO 2015151005A3 IB 2015052297 W IB2015052297 W IB 2015052297W WO 2015151005 A3 WO2015151005 A3 WO 2015151005A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
caffeic acid
treating cancer
phenethyl ester
acid phenethyl
Prior art date
Application number
PCT/IB2015/052297
Other languages
Spanish (es)
French (fr)
Other versions
WO2015151005A2 (en
Inventor
Enrique Ramón ÁNGELES ANGUIANO
Ana María VELÁZQUEZ SÁNCHEZ
Víctor Hugo VÁZQUEZ VALADEZ
Víctor Hugo ABREGO REYES
Pablo Arturo MARTÍNEZ SORIANO
Mónica BASSET RUÍZ
Andrés ROMERO ROJAS
Sandra DÍAZ BARRIGA ARCEO
Brígida del Cármen CAMACHO ENRÍQUEZ
Alfonso DUEÑAS GONZÁLEZ
Saúl VILLA TREVIÑO
Original Assignee
Universidad Nacional Autónoma de México
Centro De Investigación Y De Estudios Avanzados Del Instituto Politécnico Nacional
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Nacional Autónoma de México, Centro De Investigación Y De Estudios Avanzados Del Instituto Politécnico Nacional filed Critical Universidad Nacional Autónoma de México
Publication of WO2015151005A2 publication Critical patent/WO2015151005A2/en
Publication of WO2015151005A3 publication Critical patent/WO2015151005A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/13—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates specifically to the chemical synthesis, identification and determination of the chemical structure of analogues of the caffeic acid phenethyl ester (CAPE) with activity against cancer, especially against liver cancer. The invention also relates to the production of pharmaceutical compositions containing same and to the use thereof for preventing and treating cancer by means of the chemoprotective capacity thereof.
PCT/IB2015/052297 2014-04-01 2015-03-28 Analogue compounds of the caffeic acid phenethyl ester and the use thereof for preventing and treating cancer WO2015151005A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2014003941A MX359974B (en) 2014-04-01 2014-04-01 Analogue compounds of the caffeic acid phenethyl ester and the use thereof for preventing and treating cancer.
MXMX/A/2014/003941 2014-04-01

Publications (2)

Publication Number Publication Date
WO2015151005A2 WO2015151005A2 (en) 2015-10-08
WO2015151005A3 true WO2015151005A3 (en) 2016-01-07

Family

ID=54241390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/052297 WO2015151005A2 (en) 2014-04-01 2015-03-28 Analogue compounds of the caffeic acid phenethyl ester and the use thereof for preventing and treating cancer

Country Status (2)

Country Link
MX (1) MX359974B (en)
WO (1) WO2015151005A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11760715B2 (en) 2016-03-03 2023-09-19 Université De Moncton Modulators of lipoxygenase and cyclooxygenase enzyme activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007115269A2 (en) * 2006-03-31 2007-10-11 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007115269A2 (en) * 2006-03-31 2007-10-11 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C E CARRASCO-LEGLEU ET AL.: "A single dose of caffeic acid phenetyl ester prevents initiation in a medium-term rat hepatocarcinogenesis model", WORLD JOURNAL GASTROENTEROLOGY 2006, vol. 12, no. 42, 2006, pages 6779 - 6785 *
C E CARRASCO-LEGLEU ET AL.: "Chemoprotective effect of caffeic acid phenetyl ester on promotion in a médium-term rat hepatocarcinogenesis assay", INTERNATIONAL JOURNAL CANCER 2003, vol. 108, no. 4, 2003, pages 488 - 492 *
J R MACÍAS-PÉREZ ET AL.: "The effect of caffeic acid phenetyl ester analogues in a modified resistant hepatocyte model", ANTI-CANCER DRUGS 2013, vol. 24, no. 4, pages 394 - 405 *

Also Published As

Publication number Publication date
MX359974B (en) 2018-10-05
WO2015151005A2 (en) 2015-10-08
MX2014003941A (en) 2015-09-30

Similar Documents

Publication Publication Date Title
WO2015101957A3 (en) Inhibitors of glutaminase
EP3413885A4 (en) Compositions containing tucaresol or its analogs
MX2016016666A (en) Boronic acid derivatives and therapeutic uses thereof.
MX2016015093A (en) Boronic acid derivatives and therapeutic uses thereof.
WO2015142001A3 (en) Compound having cardiotonic activity and pharmaceutical composition for preventing or treating heart failure, containing same
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
IL250882A0 (en) Novel pharmaceutical composition containing hydroxamic acid derivative or salt thereof
IL246655A0 (en) Pharmaceutical composition containing pyridylaminoacetic acid compound
MX2018015302A (en) Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same.
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
PH12016501462A1 (en) Neprilysin inhibitors
MX2022006304A (en) Compositions and methods for inhibiting the biological activity of soluble biomolecules.
MX2017007377A (en) Organic compounds.
HUE060836T2 (en) Effervescent compositions containing co-crystals of the acid part
WO2016142819A3 (en) Novel process for the preparation of ranolazine
MX2015016957A (en) Synthesis of dicarbamates from reduction products of 2-hydroxymethyl-5-furufural (hmf) and derivatives thereof.
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
EP3733212A4 (en) Pharmaceutical composition for preventing or treating cancer metastasis to lung, containing chi3l1 inhibitor as active ingredient
EP3508200A4 (en) Aqueous formulation containing 5-aminolevulinic acid or the like
WO2016020408A3 (en) Compounds for preventing ototoxicity
MX371158B (en) Organic compounds.
WO2015151005A3 (en) Analogue compounds of the caffeic acid phenethyl ester and the use thereof for preventing and treating cancer
SG11202003286YA (en) Cool-sensation imparter composition containing 2,2,6-trimethylcyclohexanecarboxylic acid derivative
EP3270916A4 (en) Methods for the chemical synthesis of pyrrole-linked bivalent compounds, and compositions thereof
WO2016011088A3 (en) Epoxyketone compounds for enzyme inhibition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15772319

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15772319

Country of ref document: EP

Kind code of ref document: A2